Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
6,42 USD | +4,39% | -0,47% | -23,84% |
08/04 | Replimune Group geeft tussentijdse resultaten voor huidkankertherapie | MT |
26/03 | Replimune Group, Inc. Kondigt wijzigingen in het management aan | CI |
Vakgebied
Aantal werknemers: 284
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sushil Patel
CEO | Chief Executive Officer | 53 | 03-05-21 |
Colin Love
FOU | Founder | 66 | 01-03-15 |
Founder | 52 | 01-03-15 | |
Robert Coffin
FOU | Founder | 59 | 01-03-15 |
Emily Hill
DFI | Director of Finance/CFO | 44 | 19-09-23 |
Chief Tech/Sci/R&D Officer | 58 | 01-12-22 | |
Comptroller/Controller/Auditor | 48 | 01-08-20 | |
Corporate Officer/Principal | 56 | 03-01-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paolo Pucci
BRD | Director/Board Member | 63 | 01-04-20 |
Joseph Slattery
BRD | Director/Board Member | 59 | 01-10-17 |
Robert Coffin
FOU | Founder | 59 | 01-03-15 |
Founder | 52 | 01-03-15 | |
Hyam Levitsky
BRD | Director/Board Member | 66 | 01-05-18 |
Kapil Dhingra
BRD | Director/Board Member | 64 | 01-07-17 |
Christy Oliger
BRD | Director/Board Member | 54 | 01-12-21 |
Dieter Weinand
BRD | Director/Board Member | 63 | 22-06-18 |
Sushil Patel
CEO | Chief Executive Officer | 53 | 03-05-21 |
Director/Board Member | 52 | 01-06-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 61 387 786 | 57 829 311 ( 94,20 %) | 0 | 94,20 % |
Bedrijfsgegevens
Replimune Group, Inc.
500 Unicorn Park Drive Suite 303
01801, Woburn
+781 222 9600
http://www.replimune.comSector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-23,84% | 378 mln. | |
+1,51% | 42,59 mld. | |
+8,57% | 40,65 mld. | |
+49,22% | 40,57 mld. | |
-12,36% | 26,77 mld. | |
+8,92% | 24,81 mld. | |
-25,13% | 18,17 mld. | |
+29,17% | 12,05 mld. | |
-3,12% | 11,7 mld. | |
+6,35% | 11,1 mld. |
- Beurs
- Aandelen
- Koers REPL
- Onderneming Replimune Group, Inc.